A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC 12-02)
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Rhenium (186Re) obisbemeda (Primary)
- Indications Astrocytoma; Diffuse intrinsic pontine glioma; Ependymoma; Glioblastoma; Glioma
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Acronyms ReSPECT; ReSPECT-GBM; ReSPECT-TM
- Sponsors Plus Therapeutics
- 14 Aug 2024 According to a Plus Therapeutics media release, data from this study will be presented at the Congress of Neurological Surgeons (CNS) Annual Conference (September 28-October 2, 2024).
- 12 Aug 2024 According to a Plus Therapeutics media release, this trial is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH).
- 02 Jul 2024 According to a Plus Therapeutics media release, the company announced that data from this study will be presented at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer on July 8, 2024 in Newry, Maine.